INTRODUCTION AND AIMS:
On-line hemodiafiltration (HDF) can efficiently remove uremic toxins, ranging from small-to large-molecular-weight toxins, by both diffusion and convection. b2-Microglobulin (MG) (MW, 11.8 kDa; Stoke's radius, 15.6A) is an important marker of dialysis efficiency. However, b2-MG is a little small as a marker for evaluation of the removal efficiency of HDF. Therefore, a1-MG (MW, 33 kDa; stokes radius, 28.4A) is preferable as a marker in HDF. The removal of a1-MG and albumin (Alb) (MW, 66 kDa; stokes radius, 35.5A) separately is difficult even by HDF. Therefore, Alb leakage during HDF is unavoidable when removing middle-and large-molecular-weight substances. In this study, we investigated the relationship between the removal efficiency of low-molecular-weight protein (LMWP) and the amount of Alb leakage in HDF. We also present here typical cases in which clinical symptoms significantly improved after efficient removal of a1-MG.
METHODS:
The study subjects were 40 patients who had undergone HDF (241 times in total) in 2017 (Qb, 265.6629.5 mL/min; Vs, 49.3610.8 L/session). The removal efficiencies of b2-MG and a1-MG and the amount of Alb leakage were evaluated. The relationship between the removal rate of each solute and the amount of Alb leakage was examined. The change in serum Alb levels in 30 patients who underwent high-efficiency HDF (removal rates of b2-MG and a1-MG, 83% and 37%, respectively; amount of Alb leakage, 4.261.6g/session) for 1 year was examined. RESULTS: Analysis of the test results showed that the removal rates of b2-MG and a1-MG were 82.0 6 4.5% and 34.7 6 9.3%, respectively. The Alb leakage was 3.9 6 1.7g/ session. Figure shows the correlations between the amount of Alb leakage and the b2-MG and a1-MG removal rates. The approximate curve of the amount of Alb leakage was closely correlated to that of a1-MG removal rate Although the MW of Alb is two times higher than that of a1-MG, the difference in Stoke's radius between them is 20%. Thus, the present study confirmed that the removal of a1-MG and Alb separately was impossible with the current dialyzer membrane. The serum Alb level of 30 patients who underwent high-efficiency HDF was 3.64 6 0.21g/dL in January 2017 and 3.64 6 0.23g/dL in December 2017, without significant change. Typical cases: 1) A case with itchiness: HDF was performed at b2-MG and a1-MG removal rates of 77% and 30%, respectively. The patient developed strong itching. The symptom disappeared after performing HDF, at the a1-MG removal rate of 43%. 2) A case with restless legs syndrome (RLS): Decreased efficiency of dialysis (a1-MG removal rate, 39%!30%) led to RLS with an International Restless Leg Syndrome Study Group Rating Scale score of 32. The symptom disappeared after performing HDF at the a1-MG removal rate of 42%. 3) A case with dialysis amyloidosis: Decreased efficiency of dialysis (a1-MG removal rate, 37%!30%) led to shoulder joint pain. The symptom greatly improved after HDF at the a1-MG removal rate of 38%. CONCLUSIONS: Efficient removal of LMWP is always associated with Alb leakage. An Alb leakage of 3 to 6 g/session is within the acceptable range. a1-MG is the most appropriate marker of the removal efficiency of HDF.
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INTRODUCTION AND AIMS:
A high-flux dialyser, incorporating an advanced polysulfone membrane offering a broad spectrum of uremic toxin elimination, has been introduced. The study aimed to compare biocompatibility profiles of four polysulfone haemodialysers, all applied in online haemodiafiltration (HDF).
METHODS:
In this explorative prospective randomized crossover study, 24 adult patients were treated thrice weekly for one week each with high-flux dialysers FX 100, xevonta Hi 23, FX CorDiax 100 or FX CorDiax 1000, respectively, all on online postdilution haemodiafiltration (HDF). Blood samples were drawn before, during and at end of treatment. Mean levels of haemocompatibility markers were calculated as well as predicted by linear mixed models with fixed effects for treatment, period interaction between treatment and period and a random subject effect. Estimates at 10 min of treatment (adjusted for pre-dialysis value), for the complete treatment [area-under-the curve (AUC)] or for relative changes (pre-to post-dialysis) were compared by dialysers (overall, and FX100 vs every other dialyser). RESULTS: Descriptive statistics showed a similar trend of each marker in all treatments. Mean concentrations of complement factors increased early in the treatment, C3a, C5a until 10 min and sC5b9 until 60 min. Estimated C3a levels at 10 min did not differ statistically significantly when comparing FX100 vs xevonta Hi 23 or FX CorDiax 100, but vs FX CorDiax 1000, with lower estimates in CorDiax1000. All dialyser showed a similar course of C5a with a slightly higher increase in case of FX 100 compared to the other dialysers. Mean leukocyte counts decreased until 10 min, this change recovered again, the only statistically significant difference was found at 10 min between xevonta Hi 23 and FX100. PMN elastase increased during the first hour. TAT increased during the treatment, whereas thrombocyte counts decreased until 30 min, similarly with all dialysers. Compared to FX100 treatments, TAT had a less pronounced increase with the FX CorDiax 1000 or xevonta Hi 23 dialyser. Compared to FX100, mean AUC estimates of kallikrein were significantly lower with the xevonta Hi 23, but not with both FX CorDiax dialysers. No dialyser or treatment related adverse events occurred with FX 100, FX CorDiax 100 or FX CorDiax 1000 hemodialyser. CONCLUSIONS: The similar courses of analysed markers during treatments support a comparable biocompatibility of studied dialysers. Some differences observed may be explained by more effective elimination of middle molecules when comparing FX100 vs new generation dialysers, or by patient factors of biocompatibility. 
